Literature DB >> 10992180

In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.

A D Santin1, P L Hermonat, A Ravaggi, S Bellone, S Pecorelli, M J Cannon, G P Parham.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the potential of dendritic cells pulsed with whole-tumor extracts derived from autologous ovarian cancer cells in eliciting a tumor-specific cytotoxic T-cell response in vitro from patients with advanced ovarian cancer. STUDY
DESIGN: CD8(+) T lymphocytes stimulated in vitro with autologous ovarian tumor lysate-pulsed dendritic cells were tested for their ability to induce a human leukocyte antigen class I-restricted cytotoxic T-lymphocyte response able to specifically kill autologous tumor cells in standard 6-hour chromium 51 cytotoxicity assays. In addition, to correlate cytotoxic activity by cytotoxic T-lymphocytes with a particular lymphoid subset, 2-color flow cytometric analysis of intracellular cytokine expression (interferon gamma and interleukin 4) at the single-cell level was performed.
RESULTS: Cytotoxic T lymphocytes specific for autologous ovarian tumor cells were elicited from 3 patients with advanced ovarian cancer. Although cytotoxic T-lymphocyte populations expressed strong cytolytic activity against autologous tumor cells, they did not lyse concanavalin A-stimulated autologous lymphocytes or autologous Epstein-Barr virus-transformed lymphoblastoid cell lines and showed negligible cytotoxicity against the natural killer cell-sensitive cell line K-562. Cytotoxic effect against the autologous tumor cells was inhibited by an anti-human leukocyte antigen class I monoclonal antibody (W6/32). It is interesting that CD8(+) cytotoxic T lymphocytes expressed variable levels of CD56, a marker that may be associated with high cytotoxic activity. Finally, most of the tumor-specific CD8(+) T cells exhibited a T(H)1 cytokine bias, and a high percentage of interferon gamma expressors among cytotoxic T lymphocytes was correlated with higher cytotoxic activity.
CONCLUSION: These data show that tumor lysate-pulsed dendritic cells can consistently induce in vitro specific CD8(+) cytotoxic T lymphocytes able to kill autologous tumor cells from patients with advanced stage ovarian cancer. This novel approach may have important implications for the treatment of residual or resistant disease with active or adoptive immunotherapy after standard surgical and cytotoxic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992180     DOI: 10.1067/mob.2000.107097

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

Review 1.  Second-line and subsequent therapy for ovarian carcinoma.

Authors:  Prema P Peethambaram; Harry J Long
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

Review 2.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

3.  Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.

Authors:  Douglas J Hanlon; Paulomi B Aldo; Lesley Devine; Ayesha B Alvero; Anna K Engberg; Richard Edelson; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2011-01-18       Impact factor: 3.886

Review 4.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

5.  HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity Studies.

Authors:  Haneen Amawi; Noor A Hussein; Chandrabose Karthikeyan; Elangovan Manivannan; Alexander Wisner; Frederick E Williams; Temesgen Samuel; Piyush Trivedi; Charles R Ashby; Amit K Tiwari
Journal:  Front Pharmacol       Date:  2017-08-02       Impact factor: 5.810

6.  A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade.

Authors:  Leonardo Mirandola; Maurizio Chiriva-Internati; Robert Bresalier; Lucia Piccotti; Fabio Grizzi; Francesco M Marincola
Journal:  J Transl Med       Date:  2019-12-19       Impact factor: 5.531

7.  Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.

Authors:  A D Santin; F Zhan; S Bellone; M Palmieri; S Cane; M Gokden; J J Roman; T J O'Brien; E Tian; M J Cannon; J Shaughnessy; S Pecorelli
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

Review 8.  Adoptive immunotherapy against ovarian cancer.

Authors:  Gloria Mittica; Sonia Capellero; Sofia Genta; Celeste Cagnazzo; Massimo Aglietta; Dario Sangiolo; Giorgio Valabrega
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.